-
21.发明申请AMINO ACID DIAMIDES IN NON ALPHA POSITION WHICH ARE USEFUL AS ADJUVANTS FOR ADMINISTRATION OF BIOLOGICAL ACTIVE AGENTS 有权作为生物活性物质管理的辅助物质的非阿尔法位置的氨基酸公开(公告)号：US20070191302A1
公开(公告)日：2007-08-16
申请号：US10563994
申请日：2004-07-23
IPC分类号： A61K31/737 , A61K31/727 , A61K31/195 , C07C237/30
CPC分类号： C07C237/42
摘要： Amino acid diamides in non α position of formula (1), wherein R1 is selected from amongst the group consisting of the functional groups alkyl, halogen, NO2, OH, OCH3 alone or associated and R2 is selected from the group consisting of functional groups H, alkyl, halogen, NO2, OH, OCH3, which are useful as adjuvants for the administration of biological active agents, as well as pharmaceutical compositions containing these diamides of formula (1) and the use thereof for the manufacture of antithrombotic medications and for the manufacture of a medication for the treatment of a disease selected from amongst the group consisting of inflammation, cancer and allergy.
摘要翻译： 式（1）的非α位的氨基酸二酰胺，其中R 1选自官能团烷基，卤素，NO 2，OH， OCH 3单独或相连，R 2选自官能团H，烷基，卤素，NO 2，OH，OCH 其可用作生物活性剂的给药辅助剂，以及含有这些式（1）的二酰胺的药物组合物及其用于制备抗血栓药物和用于制备抗血栓药物的用途 用于治疗选自炎症，癌症和过敏的疾病的药物。
-
公开(公告)号：US20230139877A1
公开(公告)日：2023-05-04
申请号：US18054356
申请日：2022-11-10
摘要： Procedure for the purification of biodegradable thermoplastic polymer particles for medical and/or pharmaceutical use without the use of organic solvents, as well as the particles obtained themselves, and the use of polymeric particles obtained by this procedure to manufacture parenteral administered medicinal products and/or implantable medical devices.
-
公开(公告)号：US20210077380A1
公开(公告)日：2021-03-18
申请号：US17104337
申请日：2020-11-25
IPC分类号： A61K9/00 , A61K31/519 , A61K47/34
摘要： Injectable depot compositions comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.
-
24.发明授权公开(公告)号：US10705037B2
公开(公告)日：2020-07-07
申请号：US16251909
申请日：2019-01-18
摘要： An analytical method employing nuclear magnetic resonance of glycosaminoglycans in general, and of heparins and low molecular weight heparins and their derivatives in particular, is provided. The method is used for identification and the relative quantification of characteristic signals by 1H-NMR and/or 1H-13C HSQC.
-
公开(公告)号：US20200085728A1
公开(公告)日：2020-03-19
申请号：US16656167
申请日：2019-10-17
IPC分类号： A61K9/00 , A61K31/519 , A61K47/34
摘要： The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.
-
26.发明申请公开(公告)号：US20190154601A1
公开(公告)日：2019-05-23
申请号：US16251909
申请日：2019-01-18
摘要： The present invention describes an analytical method by nuclear magnetic resonance of glycosaminoglycans in general, and of heparins and low molecular weight heparins and their derivatives in particular, which allows their identification and the relative quantification of its characteristic signals by 1H-NMR and/or 1H-13C HSQC.
-
公开(公告)号：US10058504B2
公开(公告)日：2018-08-28
申请号：US13690707
申请日：2012-11-30
IPC分类号： A61K9/00 , A61K47/34 , A61K31/551 , A61K31/4468 , A61K31/519 , A61K31/4196
CPC分类号： A61K9/0002 , A61K9/0024 , A61K31/4196 , A61K31/4468 , A61K31/519 , A61K31/551 , A61K47/34
摘要： Injectable depot compositions, comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.
-
公开(公告)号：US20120022020A1
公开(公告)日：2012-01-26
申请号：US13193977
申请日：2011-07-29
IPC分类号： A61K31/715
CPC分类号： A61K9/2027 , A61K9/2072
摘要： A pharmaceutical composition containing a sulfated glycosaminoglycan drug and a polycationic polymer or copolymer wherein the proportion of ammonium groups in the pharmaceutical composition is between 0.01-2.0 μmol ammonium groups/mg pharmaceutical composition, the proportion of glycosaminoglycan in the pharmaceutical form is between 15% to 50% w/w, and the pharmaceutical composition possesses a moisture content of 10% wt or less. A pharmaceutical dosage form containing the pharmaceutical composition, and their use for the treatment of diseases or disorders therapeutically responsive to the glycosaminoglycan.
摘要翻译： 含有硫酸化糖胺聚糖药物和聚阳离子聚合物或共聚物的药物组合物，其中药物组合物中铵基团的比例为0.01-2.0μmol/ mg药物组合物，药物形式中糖胺聚糖的比例为15％至 50％w / w，药物组合物的含水量为10重量％以下。 含有药物组合物的药物剂型及其用于治疗对糖胺聚糖治疗反应的疾病或病症的用途。
-
公开(公告)号：US20110238163A1
公开(公告)日：2011-09-29
申请号：US13043021
申请日：2011-03-08
CPC分类号： A61L31/14 , A61L29/085 , A61L29/14 , A61L31/10
摘要： There is provided a device comprising a body structure having one or more surfaces wherein at least one of the surfaces comprises a pH sensitive layer comprising a linear polymer, wherein the water solubility of the linear polymer increases from a first water solubility to a second water solubility at a pH trigger. A method of forming a device, and a method of preventing or mitigating infection is also described.
摘要翻译： 提供了一种包括具有一个或多个表面的主体结构的装置，其中至少一个表面包括包含线性聚合物的pH敏感层，其中线性聚合物的水溶性从第一水溶性增加到第二水溶性 在pH触发。 还描述了形成装置的方法，以及预防或减轻感染的方法。
-
公开(公告)号：US11752093B2
公开(公告)日：2023-09-12
申请号：US17672927
申请日：2022-02-16
IPC分类号： A61K9/00 , A61K31/519 , A61K47/34
CPC分类号： A61K9/0002 , A61K9/0024 , A61K31/519 , A61K47/34
摘要： The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.
-
-
-
-
-
-
-
-
-
搜索结果
42 条记录 (耗时 0.037 秒)
